GeparQuinto研究:曲妥珠单抗或拉帕替尼新辅助化疗后HER2阳性乳腺癌的生存分析
GeparQuinto III期试验显示,在HER2阳性乳腺癌患者中,拉帕替尼联合化疗的病理完全缓解率低于曲妥珠单抗联合化疗。本文报告长期随访结果:两治疗组3年无病生存、无远处转移生存和总生存无显著差异;pCR与长期结局相关;在激素受体阳性患者中,新辅助拉帕替尼6个月后辅助曲妥珠单抗12个月较曲妥珠单抗单药显著改善生存。
要点
- 两治疗组3年DFS、DDFS和OS无显著差异。
- pCR与长期结局相关,尤其激素受体阴性患者。
- 激素受体阳性患者中,拉帕替尼新辅助后曲妥珠单抗辅助显著改善OS。
核心结论
- pCR与长期结局相关。
- 在激素受体阳性肿瘤患者中,延长抗HER2治疗(新辅助拉帕替尼6个月后辅助曲妥珠单抗12个月)较曲妥珠单抗单药显著改善生存。
研究设计与样本
- GeparQuinto III期试验的长期生存分析。
- HER2阳性肿瘤患者(n=615)接受新辅助表柔比星+环磷酰胺后多西他赛联合拉帕替尼或曲妥珠单抗。
- ECH-TH组n=307,ECL-TL组n=308;所有患者接受辅助曲妥珠单抗,总疗程分别为12个月和18个月。
- 中位随访55个月。
主要发现
- 两治疗组3年DFS、DDFS和OS无显著差异。
关键数值与推荐
- pCR定义为pT0 ypN0。
临床怎么用
- pCR可作为HER2阳性乳腺癌新辅助治疗的长期结局替代指标。
- 激素受体阳性患者可考虑新辅助拉帕替尼后辅助曲妥珠单抗的延长抗HER2策略。
- 拉帕替尼联合化疗的pCR率低于曲妥珠单抗联合化疗,但长期生存无显著差异。
局限性
- 激素受体阴性患者事件数少,限制解释。
- 中位随访55个月,长期结局需更久随访确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The GeparQuinto phase III trial demonstrated a lower pathologic complete response (pCR; pT0 ypN0) rate when lapatinib was added to standard anthracycline-taxane chemotherapy compared with trastuzumab in patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer. Here, we report the long-term outcomes. Methods Patients with HER2-positive tumors (n = 615) received neoadjuvant treatment with epirubicin (E) plus cyclophosphamide (C), followed by docetaxel (T) in combination with either lapatinib (L) or trastuzumab (H; ECH-TH arm: n = 307; ECL-TL arm: n = 308). All patients received adjuvant trastuzumab for a total of 12 months and 18 months in the ECH-TH and ECL-TL arms, respectively. Median follow-up was 55 months. Results Three-year disease-free survival (DFS), distant DFS (DDFS), and overall survival (OS) were not significantly different between the two treatment arms. Long-term outcomes correlated with pCR (DFS: hazard ratio [HR], 0.63; P = .042; DDFS: HR, 0.55; P = .021; and OS: HR, 0.31; P = .004). A benefit only for OS was observed in patients who were treated with trastuzumab and achieved pCR versus no pCR (HR, 0.15; P = .010), whereas no difference was found in patients with pCR versus without pCR in the lapatinib arm. DFS and DDFS remained unchanged in both treatment arms according to hormone receptor status, whereas OS was significantly better in hormone receptor-positive patients who were treated with neoadjuvant lapatinib (HR, 0.32; P = .019), followed by adjuvant trastuzumab. No difference was observed in hormone receptor-negative patients; however, the small number of events limits this interpretation. Within the hormone receptor-negative cohort, pCR was significantly associated with DFS, DDFS, and OS ( P = .002, .005, and .002, respectively). Conclusion pCR correlated with long-term outcome. In patients with hormone receptor-positive tumors, prolonged anti-HER2 treatment-neoadjuvant lapatinib for 6 months, followed by adjuvant trastuzumab for 12 months-significantly improved survival compared with anti-HER2 treatment with trastuzumab alone.
引用
- Untch M, von Minckwitz G, Gerber B, et al. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44). J Clin Oncol. 2018. PMID: 29543566. doi:10.1200/JCO.2017.75.9175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。